Stem cell-based technologies are one of the most promising approaches in the further advancement of cell therapy and regenerative medicine. Also, great hopes are linked to using stem cells as a tool for drug discovery. In order to make progress towards commercialization, researchers in the field are evaluating standardization of their cultivation and efficient scale-up.
Widely established in traditional cell culture, controlled bioreactors have the potential to establish reproducible expansion of stem cells. They provide extensive options for monitoring and control of key parameters such as pH and dissolved oxygen in real-time and facilitate a controlled differentiation of the cells. Through scalable bioreactor design, results obtained in small scale can be transferred to larger working volumes while maintaining optimum mass transfer.
Our infield application specialist Dr. Philipp Nold gave an interview to Cell & Gene Therapy Insights in which he talks about advancements and challenges in stem cell bioprocessing and what the sector might learn from biologics production.
Since the pioneering development of cell reprogramming by Shinya Yamanaka in 2006, induced pluripotent stem cells (iPSCs) have risen to be the most promising alternative to ethically problematic embryonic stem cells. Controlled cultivation and scale-up in clinical grade as well as ways to control their differentiation towards their final destiny will be key steps towards commercial use of these cells.
A team of researchers from
developed a bioprocess for the large-scale manufacturing of cardiomyocytes derived from a variety of healthy and diseased hiPSC lines. They expanded hiPSCs as cell aggregates in a DASbox® Mini Bioreactor System and scaled-up the process using a BioFlo 320 bioprocess control system.
Mesenchymal stem cells (MSCs) are multipotent cells derived from the bone marrow, from adipose tissue, cord blood or other tissues related to the embryonic mesoderm. They are relatively easy to obtain and have great potential for cell therapy and drug screening.
Various MSCs have been successfully cultivated in stirred-tank bioreactors.
The Stem Cell Community Day connects researchers from all over the world to review recent advances in the area of stem cells, with a special focus on cultivation in stirred-tank bioreactors.
At our 1st Stem Cell Community Day in April 2017 we brought together experts from industry and academia, to discuss latest achievements, challenges, and chances in stem cell bioprocessing for research and commercial manufacturing.
eBook: Advancing medicine - Can cell and gene therapies paint a picture of perfect future health? (The Medicine Maker, sponsored by Eppendorf) 3.2 MB, PDF